Medical isotope developer IsoRay has completed the expansion of a new production space for its Proxcelan cesium-131 brachytherapy seeds for the treatment of prostate cancer.
In September, the Richland, WA-based company will begin production in a 20,000-sq-ft facility located at Energy Northwest's Applied Engineering Laboratory (APEL), also in Richland.
IsoRay will combine its radioactive and nonradioactive production, as well as some administrative offices, into the space, consolidating its U.S. operations into a single location and allowing the company to increase its production of brachytherapy seeds to more than 100,000 per month. The finished seeds will also be handled, assayed, and packaged at APEL.
By AuntMinnie.com staff writers
August 30, 2007
Related Reading
IsoRay to join AMEX, April 16, 2007
IsoRay continues cesium-131 placements, April 5, 2007
IsoRay scores additional financing, March 23, 2007
IsoRay adds cesium-131 sites, January 17, 2007
IsoRay sales triple in fiscal Q1, November 15, 2006
Copyright © 2007 AuntMinnie.com
